Sin­ga­pore to get a new man­u­fac­tur­ing, R&D site to fight help in­fec­tious dis­eases

Hille­man Lab­o­ra­to­ries is open­ing a vac­cine and bi­o­log­ics de­vel­op­ment hub in Sin­ga­pore to aid the com­pa­ny’s jour­ney to de­vel­op af­ford­able vac­cines against in­fec­tious dis­eases.

A 30,000-square-foot site will go up at 138 De­pot Road in Biopo­lis at a brand new R&D cen­ter at the Biopo­lis in­dus­tri­al park. The project will cost around $58 mil­lion with a two-year build­out ex­pect­ed.

The man­u­fac­tur­ing site will sup­ply clin­i­cal tri­al ma­te­ri­als for up to Phase II de­vel­op­ment, and the R&D fa­cil­i­ty will be work­ing on can­di­date se­lec­tion, de­sign, the man­u­fac­tur­ing process de­vel­op­ment, and pre­clin­i­cal stud­ies. The two lo­ca­tions will work to­geth­er to pro­vide con­cept-to-Phase II ser­vices.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER